RxDoctor Payments Data

Alain Litwin

Addiction Medicine · Bronx, NYNPI 1366527368

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 89.6% of it on its own, with 4 other manufacturers making up the rest. 2025 is the largest year on record at $66,291, 4.9 times the $13,600 reported in 2019. Among addiction medicine clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$123,714in general payments, 2019–2025

Across 145 payments — averaging $853.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$111K
  • Merck$13K
  • Siemens Medical Solutions USA, Inc.$130
  • AbbVie$58
  • Alkermes, Inc.$26
$1,644,534in research payments, 2019–2025

Across 288 payments — averaging $5710.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Indivior Inc.$1M
  • Gilead$628K

What the payments were for

  • Consulting fees$45,01736%
  • Speaking & faculty fees$62,67951%
  • Travel & lodging$12,70010%
  • Food & beverage$3,3053%
  • Education$130%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead138$110,849
Merck2$12,650
Siemens Medical Solutions USA, Inc.1$130
AbbVie2$58
Alkermes, Inc.2$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$123,714 in reported general payments places this provider in the 95th percentile of 125 addiction medicine providers in New York.

See all addiction medicine providers in New York

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl32$2,725

Paid to pharmacies, not to this prescriber.

Other addiction medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →